Sangamo BioSciences to Host Conference Call to Discuss Results From Phase 2b Diabetic Neuropathy Trial Monday 8:30am

by Benzinga Staff

September 30, 2011 6:13 PM | 22 seconds read | Make a Comment

Sangamo BioSciences

SGMO

today announced that the company will hold a teleconference and webcast at 8:30 am ET, on Monday, October 3, 2011, to discuss results of the Phase 2b clinical trial from its ZFP Therapeutic program to develop SB-509 as a treatment for diabetic neuropathy. A press release summarizing the data from the trial will be issued at 7:00 am ET on Monday prior to this call.

Market News and Data brought to you by Benzinga APIs

Posted In: News FDA Events After-Hours Center Movers Press Releases General

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!